Cargando…

Prediction of Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer with High PD-L1 Expression Using Baseline CT Disease Quantification and Smoking Pack Years

Health Canada approved pembrolizumab in the first-line setting for advanced non-small-cell lung cancer with PD-L1 ≥ 50% and no EGFR/ALK aberration. The keynote 024 trial showed 55% of such patients progress with pembrolizumab monotherapy. We propose that the combination of baseline CT and clinical f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Silver, Ali, Ho, Cheryl, Ye, Qian, Zhang, Jianjun, Janzen, Ian, Li, Jessica, Martin, Montgomery, Wu, Lang, Wang, Ying, Lam, Stephen, MacAulay, Calum, Melosky, Barbara, Yuan, Ren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297400/ https://www.ncbi.nlm.nih.gov/pubmed/37366902 http://dx.doi.org/10.3390/curroncol30060419

Ejemplares similares

Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
por: Chang, Hao‐Chun, et al.
Publicado: (2020)

Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
por: Fiorelli, Alfonso, et al.
Publicado: (2019)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
por: Liu, Qiao, et al.
Publicado: (2022)

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
por: Takumida, Hiroshi, et al.
Publicado: (2021)

Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy
por: Hearon, Bernard F., et al.
Publicado: (2020)

Automated PD-L1 Scoring for Non-Small Cell Lung Carcinoma Using Open-Source Software
por: Naso, Julia R., et al.
Publicado: (2021)

Optical Computed-Tomographic Microscope for Three-Dimensional Quantitative Histology
por: Chamgoulov, Ravil, et al.
Publicado: (2004)

Quantitative Histopathological Analysis of CIN Sections
por: Guillaud, Martial, et al.
Publicado: (2006)

Diffuse optical microscopy for quantification of depth-dependent epithelial backscattering in the cervix
por: Bodenschatz, Nico, et al.
Publicado: (2016)

Opening the Black Box: the Relationship between Neural Networks and Linear Discriminant Functions
por: Kemp, Roger A., et al.
Publicado: (1997)

Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?
por: Mienko, Fiona, et al.
Publicado: (2020)

Surgery for Crohn’s disease: upfront or last resort?
por: Ahmed Ali, U, et al.
Publicado: (2022)

Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
por: Cristescu, Razvan, et al.
Publicado: (2022)

Quantification of confocal fluorescence microscopy for the detection of cervical intraepithelial neoplasia
por: Sheikhzadeh, Fahime, et al.
Publicado: (2015)

Detection of Malignancy Associated Changes in Cervical Cell Nuclei Using Feed-Forward Neural Networks
por: Kemp, Roger A., et al.
Publicado: (1997)

Efficacy and safety of pembrolizumab monotherapy in EGFR-mutant squamous cell lung cancer with PD-L1 over-expression: A case report
por: Liu, Qiu-Xia, et al.
Publicado: (2022)

Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial
por: Matsumoto, Hiromi, et al.
Publicado: (2021)

A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non‐small cell lung cancer
por: Isono, Taisuke, et al.
Publicado: (2021)

Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer
por: Muro, Kei, et al.
Publicado: (2023)

Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study
por: Jung, Hyun Ae, et al.
Publicado: (2022)

A stepwise framework for the normalization of array CGH data
por: Khojasteh, Mehrnoush, et al.
Publicado: (2005)

FACADE: a fast and sensitive algorithm for the segmentation and calling of high resolution array CGH data
por: Coe, Bradley P., et al.
Publicado: (2010)

Pre-profiling factors influencing serum microRNA levels
por: MacLellan, Sara A, et al.
Publicado: (2014)

Quality Assurance System Using Statistical Process Control: An Implementation for Image Cytometry
por: Chiu, David, et al.
Publicado: (2004)

Phase 2 study of first‐line pembrolizumab monotherapy in elderly patients with non‐small‐cell lung cancer expressing high PD‐L1
por: Masuda, Takeshi, et al.
Publicado: (2022)

The Three P's: Parotid, PD-L1, and Pembrolizumab
por: Wiggins, Amanda, et al.
Publicado: (2019)

Investigation of Molecular Interactions Mechanism of Pembrolizumab and PD-1
por: Wang, Simiao, et al.
Publicado: (2023)

Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data
por: Velcheti, Vamsidhar, et al.
Publicado: (2022)

PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab
por: George, Saby, et al.
Publicado: (2018)

Submillimeter diameter rotary-pullback fiber-optic endoscope for narrowband red-green-blue reflectance, optical coherence tomography, and autofluorescence in vivo imaging
por: Buenconsejo, Andrea Louise, et al.
Publicado: (2019)

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series
por: Rose, Peter G., et al.
Publicado: (2023)

Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100
por: Nishio, Shin, et al.
Publicado: (2020)

Complete remission of advanced lung adenocarcinoma with first-line pembrolizumab monotherapy: Two case reports
por: Gohara, Kazuki, et al.
Publicado: (2021)

Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: A prospective observational study
por: Shiotsu, Shinsuke, et al.
Publicado: (2022)

Association of Celiac Disease With Pembrolizumab
por: Sethi, Ashish, et al.
Publicado: (2021)

PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy
por: Möhn, Nora, et al.
Publicado: (2021)

Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
por: De Giglio, Andrea, et al.
Publicado: (2022)

In Vitro Model for Studying Malignancy Associated Changes
por: Sun, Xiao Rong, et al.
Publicado: (2003)

How selecting best upfront therapy for metastatic disease?—Focus on ROS1-rearranged disease
por: Landi, Lorenza, et al.
Publicado: (2020)

2022: the year in cardiovascular disease – the year of upfront lipid lowering combination therapy
por: Banach, Maciej, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j528d4ua8p0l9hh74pf2qanghp